What it is
ARA-290 is a small, 11-amino-acid synthetic peptide modeled after the structural layout of erythropoietin (EPO). However, unlike EPO, it does not prompt your body to manufacture more red blood cells—meaning it acts like a selective messenger focused entirely on tissue preservation without changing your blood counts.
Main Benefits
- Nerve Repair Support: Studied for its ability to promote small nerve fiber regrowth and restore peripheral nerve health.
- Inflammation Reduction: Helps calm down overly active immune responses by selectively targeting the Innate Repair Receptor (IRR).
- Neuropathic Pain Relief: Frequently investigated for reducing chronic burning or stinging pain linked to nerve damage without conventional analgesic numbing.
How It’s Typically Used
In professional clinical trials and research environments, ARA-290 is prepared as a lyophilized powder and typically administered via subcutaneous injection. There are no human dosing protocols or guidelines provided here.
Potential Downsides
General observations point to mild, temporary local irritation at the injection site, transient headaches, or brief instances of digestive upset. Long-term human impacts remain restricted due to limited data windows.
Who Might Consider This?
Researchers and clinical candidates investigating alternatives for diabetic neuropathy, chronic small-fiber nerve pain, or severe inflammatory tissue stresses under professional medical oversight.
Strong Disclaimer: This is for informational purposes only. Not medical advice. Peptides are not FDA-approved for most uses discussed. Consult a doctor. Some are research compounds only. ARA-290 is classified primarily as an unapproved research compound or investigational drug.